학술논문

Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
Document Type
Journal
Source
EUROPEAN UROLOGY ONCOLOGY; JUN 2021, 4 3, p502-p505, 4p.
Subject
Language
English
ISSN
25889311